Top

08-31-2018 | Retinopathy | Article

RETRACTED ARTICLE: Could Intensive Blood Pressure Control Really Reduce Diabetic Retinopathy Outcomes? Evidence from Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials

Journal: Diabetes Therapy

Authors: Jian-Bo Zhou, Zhi-Hui Song, Lu Bai, Xiao-Rong Zhu, Hong-Bing Li, Jin-Kui Yang

Publisher: Springer Healthcare

Abstract

Introduction

To explore the accumulated evidence concerning the effect of intensive blood pressure control on the incidence and progression of diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR) and macular edema (ME).

Methods

A number of electronic databases were searched including PubMed, EMBASE, CINAHL, Cochrane Library, conferences and proceedings. Randomized controlled trials comparing intensive blood pressure targets with conventional blood pressure targets in patients with type 2 diabetes were included. The definition of intensive versus conventional blood pressure targets was from the pertinent original studies. Meta-analyses and trial sequential analyses of randomized trials were analyzed in STATA.

Results

Eight trials randomizing 6989 patients were assessed and reviewed in full text; 3749 vs. 3240 were in each arm (intensive vs. conventional). All trials had a low risk of bias. Intensive blood pressure control supported a 17% reduction in the incidence of DR (relative risk 0.83, 95% confidence interval 0.72–0.95). Trial sequential analyses confirmed that sufficient evidence indicated a relative risk reduction above 17% for the incidence of DR when intensive blood pressure control was targeted. Heterogeneity was absent (I² = 0%; P = 0.56). No statistically significant effect was found for intensive blood pressure targeting on the progress of DR (relative risk 0.94, 95% confidence interval 0.81–1.08). TSA showed that insufficient evidence had been found, although the Z value line appeared to have a tendency of approaching the futility boundaries. There were also no statistically significant effects on the incidence of PDR and ME (TSA-adjusted CI 0.84–1.12).

Conclusion

Intensive blood pressure control reduced the relative risk of incidence of DR by 17%. The available data were insufficient to prove or refute a relative risk reduction for the progression of DR or incidence of PDR and ME at a magnitude of 15%.

Sabanayagam C, Yip W, Ting DS, Tan G, Wong TY. Ten emerging trends in the epidemiology of diabetic retinopathy. Ophthalmic Epidemiol. 2016;23(4):209–22.CrossRefPubMed

Malek M, Khamseh ME, Aghili R, Emami Z, Najafi L, Baradaran HR. Medical management of diabetic retinopathy: an overview. Arch Iran Med. 2012;15(10):635–40.PubMed

Ferris FL. How effective are treatments for diabetic retinopathy? JAMA. 1993;269(10):1290–1.CrossRefPubMed

Ohashi K, Hayashi T, Watanabe Y, Hara K, Ukichi R, Asano H, Suzuki H, Yamashiro K, Tojo K, Sakamoto M, Utsunomiya K. Primary aldosteronism with type 2 diabetes mellitus requires more antihypertensive drugs for blood pressure control: a retrospective observational study. J Clin Med Res. 2018;10(1):56–62.CrossRefPubMed

Ke CH, Morgan S, Smolina K, Gasevic D, Qian H, Khan NA. Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada. BMJ Open. 2017;7(8):e013808.CrossRefPubMedPubMedCentral

Sjølie AK, Dodson P, Hobbs FR. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int J Clin Pract. 2011;65(2):148–53.CrossRefPubMed

Jeng CJ, Hsieh YT, Yang CM, Yang CH, Lin CL, Wang IJ. Diabetic retinopathy in patients with diabetic nephropathy: development and progression. PLoS One. 2016;11(8):e0161897.CrossRefPubMedPubMedCentral

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.CrossRefPubMedCentral

Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.CrossRefPubMed

10.

Beulens JW, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009;52:2027–36.CrossRefPubMed

11.

Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the action to control cardiovascular risk in diabetes eye study. Ophthalmology. 2014;121:2443–51.CrossRefPubMed

12.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRef

13.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N, DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372(9647):1385–93.CrossRefPubMed

14.

Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156–63.CrossRefPubMed

15.

Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study. Diabetes Care. 2016;39(7):1089–100.CrossRef

16.

Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M, ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392–406.CrossRefPubMed

17.

Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control z in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–97.CrossRefPubMed

18.

Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial. Hypertension. 2011;58(5):776–83.CrossRefPubMed

19.

Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93.CrossRefPubMed

20.

Higgins JPT, Green S. Cochrane handbook for systematic reviews of intervention 5.0.0. Cochrane Collaboration, 2008 (Available from cochrane-handbook.org).

21.

Davey Smith G, Egger M. Meta-analyses of randomized controlled trials. Lancet. 1997;350:1182.CrossRefPubMed

22.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentral

23.

Crippa A, Khudyakov P, Wang M, Orsini N, Spiegelman D. A new measure of between-studies heterogeneity in meta-analysis. Stat Med. 2016;35(21):3661–75.CrossRefPubMed

24.

Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ, GRADE Working Group. What is ‘‘quality of evidence’’ and why is it important to clinicians? BMJ. 2008;336:995–8.CrossRefPubMedPubMedCentral

25.

Fraser-Bell S, Symes R, Vaze A. Hypertensive eye disease: a review. Clin Exp Ophthalmol. 2017;45(1):45–53.CrossRefPubMed

26.

Cardoso CRL, Leite NC, Dib E, Salles GF. Predictors of development and progression of retinopathy in patients with type 2 diabetes: importance of blood pressure parameters. Sci Rep. 2017;7(1):4867.CrossRefPubMedPubMedCentral

27.

Wat N, Wong RL, Wong IY. Associations between diabetic retinopathy and systemic risk factors. Hong Kong Med J. 2016;22(6):589–99.PubMed

28.

Do DV, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:CD006127.PubMed

29.

Wang B, Wang F, Zhang Y, Zhao SH, Zhao WJ, Yan SL, Wang YG. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(4):263–74.CrossRefPubMed

30.

Jin P, Peng J, Zou H, Wang W, Fu J, et al. The 5-year onset and regression of diabetic retinopathy in Chinese type 2 diabetes patients. PLoS One. 2014;9(11):e113359. https://doi.org/10.1371/journal.pone.0113359.CrossRefPubMedPubMedCentral

31.

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »